Kronos Bio Q4 EPS $(0.43) Beats $(0.52) Estimate, Sales $2.29M Beat $1.52M Estimate, Cash Balance of $175.0M
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio (NASDAQ:KRON) reported Q4 earnings with losses of $(0.43) per share, surpassing the $(0.52) estimate, marking a 23.21% improvement from last year. Sales reached $2.29M, exceeding the $1.52M forecast. The company's cash balance stands at $175.0M.
March 21, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio reported better-than-expected Q4 earnings and sales, with a significant year-over-year improvement and a strong cash balance.
Beating both EPS and sales estimates typically leads to positive investor sentiment, potentially driving up the stock price in the short term. The reported year-over-year improvement and a strong cash balance further bolster the company's financial health, making it an attractive investment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100